Sessa Capital Im, L.P. Provention Bio, Inc. Transaction History

Sessa Capital Im, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$6.7 - $24.21 $40.2 Million - $145 Million	-6,000,000 Reduced 40.33%	8,879,023 $214 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $30.5 Million - $49.9 Million	8,879,023 Added 147.98%	14,879,023 $67 Million
Q1 2022 May 16, 2022	BUY	$3.4 - $7.88 $355,215 - $823,263	104,475 Added 1.77%	6,000,000 $43.9 Million
Q4 2021 Feb 14, 2022	BUY	$5.59 - $7.39 $9.51 Million - $12.6 Million	1,700,409 Added 40.53%	5,895,525 $33.1 Million
Q3 2021 Nov 15, 2021	BUY	$5.66 - $8.33 $7.97 Million - $11.7 Million	1,408,158 Added 50.53%	4,195,116 $26.8 Million
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $18.7 Million - $30.8 Million	2,786,958 New	2,786,958 $23.5 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Sessa Capital Im, L.P., based on Form 13F filings with the SEC.

Stay updated on Sessa Capital Im, L.P. with notifications on news.